- Home
- LH vs UTHR Comparison
LH vs UTHR Comparison
Compare LH & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LH
- UTHR
- Stock Information
- Founded
- LH 1971
- UTHR 1996
- Country
- LH United States
- UTHR United States
- Employees
- LH N/A
- UTHR N/A
- Industry
- LH Medical Specialities
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- LH Health Care
- UTHR Health Care
- Exchange
- LH Nasdaq
- UTHR Nasdaq
- Market Cap
- LH 19.2B
- UTHR 16.2B
- IPO Year
- LH N/A
- UTHR 1999
- Fundamental
- Price
- LH $226.25
- UTHR $357.55
- Analyst Decision
- LH Buy
- UTHR Buy
- Analyst Count
- LH 16
- UTHR 14
- Target Price
- LH $258.29
- UTHR $370.86
- AVG Volume (30 Days)
- LH 487.4K
- UTHR 268.9K
- Earning Date
- LH 02-13-2025
- UTHR 10-30-2024
- Dividend Yield
- LH 1.27%
- UTHR N/A
- EPS Growth
- LH N/A
- UTHR 25.10
- EPS
- LH 5.14
- UTHR 22.72
- Revenue
- LH $12,712,800,000.00
- UTHR $2,756,200,000.00
- Revenue This Year
- LH $9.99
- UTHR $26.32
- Revenue Next Year
- LH $6.20
- UTHR $10.37
- P/E Ratio
- LH $44.07
- UTHR $15.73
- Revenue Growth
- LH 5.43
- UTHR 25.04
- 52 Week Low
- LH $191.97
- UTHR $208.62
- 52 Week High
- LH $247.99
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- LH 38.09
- UTHR 41.93
- Support Level
- LH $228.84
- UTHR $358.82
- Resistance Level
- LH $233.97
- UTHR $378.27
- Average True Range (ATR)
- LH 4.22
- UTHR 9.60
- MACD
- LH -1.50
- UTHR -0.51
- Stochastic Oscillator
- LH 0.00
- UTHR 5.07
About LH Laboratory Corporation of America Holdings
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
About UTHR United Therapeutics Corporation
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.